Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveHIV InfectionsReverse Transcriptase InhibitorsCD4 Lymphocyte CountDrug Resistance, Multiple, ViralZidovudineHIV-1Drug Therapy, CombinationAnti-Retroviral AgentsDrug Resistance, ViralDrug TherapyViral LoadHIV Protease InhibitorsHIVAcquired Immunodeficiency SyndromeMedication AdherenceNevirapinePatient ComplianceSouth AfricaInfectious Disease Transmission, VerticalBenzoxazinesAIDS-Related Opportunistic InfectionsStavudineTreatment OutcomeRNA, ViralCohort StudiesRitonavirOrganophosphonatesLamivudineLopinavirHIV-Associated Lipodystrophy SyndromeTreatment FailureHIV SeropositivityPregnancy Complications, InfectiousDrug MonitoringUgandaAdenineIndinavirViremiaImmune Reconstitution Inflammatory SyndromeHIV Reverse TranscriptaseCD4-Positive T-LymphocytesBotswanaLost to Follow-UpPyrimidinonesProspective StudiesNelfinavirDrug Administration ScheduleDidanosineRetrospective StudiesTime FactorsAIDS Dementia ComplexMalawiRisk FactorsFollow-Up StudiesDideoxynucleosidesHIV ProteaseAnti-Arrhythmia AgentsCoinfectionAntitubercular AgentsCote d'IvoireAfrica South of the SaharaDrug CostsCross-Sectional StudiesDirectly Observed TherapyPharmacogeneticsZambiaDrug InteractionsPrevalenceAntiviral AgentsVirus ReplicationLymphoma, AIDS-RelatedDisease ProgressionLipodystrophyOxazinesTuberculosisPregnancyAntihypertensive AgentsSaquinavirGenotypeAfrica, SouthernDeveloping CountriesDrug-Related Side Effects and Adverse ReactionsZimbabweTreatment RefusalUnited StatesDrugs, GenericHIV Wasting SyndromeCytomegalovirus RetinitisHypolipidemic AgentsIncidenceLongitudinal StudiesClinical Trials as TopicPlasmaLesothopol Gene Products, Human Immunodeficiency VirusPharmacistsMutationMultivariate Analysis